Rhythm Pharmaceuticals First Quarter 2022 Financial Results and Business Update May 3, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations statements regarding the potential, safety, ef ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chair, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Linda Shapiro - Chief Medical Officer Hunter Smith - Chief Financial Officer Yann Mazabraud - Executive Vice President, Head of International Conference Call Participants Derek Archila - Wells Fargo Jos ...

Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity April 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical prog ...

Start Time: 08:00 January 1, 0000 9:02 AM ET Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2021 Earnings Conference Call March 01, 2022, 08:00 AM ET Company Participants David Meeker - Chairman, President and CEO Linda Shapiro - CMO Hunter Smith - CFO Yann Mazabraud - EVP, Head of International Jennifer Chien - EVP, Head of North America David Connolly - Head of IR and Corporate Communications Conference Call Participants Phil Nadeau - Cowen and Company Joseph Stringer - Needham & Company Michael Higgins - ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R ...

Rhythm Pharmaceuticals Fourth Quarter / Year End 2021 Financial Results March 1, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations statements regarding the potential, safety, efficacy, ...

Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity November 2021 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2021 Earnings Conference Call November 2, 2021 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & Chief Executive Officer Linda Shapiro - Chief Medical Officer Jennifer Chien - Executive Vice President, Head of North America Hunter Smith - Chief Financial Officer Conference Call Participants Phil Nadeau - Cowen and Co. Joseph Stringer - Needham & Company Corinne Jenkins - Go ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...